Navigation Links
HeartWare Presentation at the Oppenheimer 23rd Annual Healthcare Conference to be Webcast
Date:12/6/2012

FRAMINGHAM, Mass. and SYDNEY, Dec. 6, 2012 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR - ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that CEO Doug Godshall is scheduled to present at the Oppenheimer 23rd Annual Healthcare Conference at 10:00 a.m. EST on Thursday, December 13, 2012.  The conference is being held December 12-13 at the Waldorf-Astoria in New York City.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com.  A replay of the webcast will be available for 90 days at the site after the presentation.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-support circulatory assist device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HeartWare System is approved in the United States for the intended use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure, and has received CE Marking in the European Union and has been used to treat patients in 27 international countries. The device is also currently the subject of a U.S. clinical trial for destination therapy. For additional information, please visit the Company's website at www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2
'/>"/>

SOURCE HeartWare International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
2. Heartware Schedules First Quarter Conference Call And Webcast
3. HeartWare Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference to be Webcast
4. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
5. HeartWare International Receives CE Mark Addendum, Expanding Label to Include All Patients at Risk of Death From Refractory, End-Stage Heart Failure
6. HeartWare Names Peter F. McAree Chief Financial Officer
7. HeartWare Schedules Second Quarter Conference Call And Webcast
8. HeartWare Completes Acquisition Of World Heart Corporation
9. HeartWare Reports Second Quarter 2012 Results
10. HeartWare Presentation at the 2012 Wedbush PacGrow Lifesciences Management Access Conference to be Webcast
11. HeartWare Presentation At The Canaccord Genuity 32nd Annual Growth Conference To Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- Cryoport, Inc. (OTCBB: CYRX) today announced financial results ... Recent Operating Highlights , Achieved ... month period ended June 30, 2014 compared to the ... further expand Cryoport,s global reach using the ,powered by ... Immudex, an immunotherapy and vaccine development services company, to ...
(Date:7/31/2014)... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... 2014, on Thursday, August 7, 2014 before markets open. ... and conference call at 8:00 a.m. Eastern time (5:00 ... the call and webcast to discuss financial results and ... by calling (800) 708-4540 (domestic) or (847) 619-6397 (international), ...
(Date:7/31/2014)...  Celsion Corporation (NASDAQ: CLSN ) announced ... to discuss its second quarter 2014 financial results at ... participate in the call, interested parties may dial 1-800-533-7954 ... and ask for the Celsion Corporation Second Quarter 2014 ... before the call is scheduled to begin. The call ...
Breaking Medicine Technology:Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 2Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 3Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 4Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 5Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 6Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 7Cryoport Reports 92% Revenue Growth for First Quarter of Fiscal 2015 8Orexigen Therapeutics to Host Second Quarter 2014 Financial Results Conference Call and Webcast 2Celsion Corporation to Hold Second Quarter 2014 Financial Results 2
... PARK, N.J., Jan. 25, 2012  Shionogi Inc., the U.S.-based ... results from two studies published online today in the ... first study, a randomized, double-blind, placebo-controlled phase III trial ... with problem drooling due to neurologic conditions demonstrated a ...
...  Amorcyte, LLC, a NeoStem, Inc. company (NYSE Amex: ... of the first patient in the Amorcyte PreSERVE ... study is a multicenter, randomized, double-blind, placebo-controlled clinical ... infarct-related artery infusion of AMR-001, an autologous bone ...
Cached Medicine Technology:Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 2Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 3Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 4Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 5Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 6Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 7Study Data Show CUVPOSA® Reduced Chronic Severe Drooling in Patients Ages 3-16 Years-Old with Neurologic Conditions 8Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 2Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 3Amorcyte, a NeoStem Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 4
(Date:7/31/2014)... (PRWEB) July 31, 2014 LDM Global ... eDiscovery pricing model that is simplified and predictable with ... size. As a leading international provider of legal ... agencies it has become glaringly apparent that both the ... ballooning eDiscovery budgets and the complex pricing structure that ...
(Date:7/31/2014)... 2014 (HealthDay News) -- With the World Health Organization ... Ebola outbreak has risen to 729, the U.S. ... a travel warning for,the region. The "Level 3 ... affected countries -- Guinea, Liberia and Sierra Leone -- ... is worsening in West Africa," CDC Director Dr. Tom ...
(Date:7/31/2014)... Ontario (PRWEB) July 31, 2014 Setting goals ... seen on blogs on successful tips to weight loss. Fitness ... goals for over 8 years, and has worked with 6000 ... trainers. “We have had the chance to monitor why customers ... stop exercising, how long they stick to their program, whether ...
(Date:7/31/2014)... NY (PRWEB) July 31, 2014 The VitalSleep anti ... lower jaw forward to help open a snorers airway to quiet ... anti-snoring remedy helped her relationship with her husband by allowing ... a 46 years old. My snoring began about 15 years ago ... husband and children could not sleep and had to head downstairs ...
(Date:7/31/2014)... New York (PRWEB) July 31, 2014 ... grow, as Bernstein Liebhard LLP notes that Johnson ... it plans to voluntarily remove its power morcellators ... a report from Bloomberg.com, the company said it ... benefits associated with the devices remain uncertain.* , ...
Breaking Medicine News(10 mins):Health News:LDM Global Announces Predictable Simple Fixed-Fee Pricing 2Health News:CDC Issues Travel Warning as West Africa Ebola Outbreak Worsens 2Health News:Fitness on the Go's Rewards Program Helps Clients Reach Their Goals 2Health News:New Snoring Mouthpiece Reviews from VitalSleep 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 2Health News:Uterine Morcellation Controversy Grows, as Bernstein Liebhard LLP Notes Johnson & Johnson Decision to Withdraw Power Morcellators from Market 3
... quit, particularly for some teens and African-Americans, who have ... by a team of researchers. , Recent studies have ... have a lower quit rate than comparable smokers of ... suggested in the report is that the menthol effect ...
... ARBOR, Mich. Black people with early stage liver cancer ... disease, according to a new study from the University of ... percent of white liver cancer patients were alive but only ... patients were. Median survival times ranged from 10 months for ...
... surgery for upper airway and digestive track malignant tumors ... based on patient function and survival, according to University ... squamous cell carcinomas account for about 4 percent of ... Currently the standard minimally invasive surgery for these tumors ...
... Reporter , MONDAY, Dec. 20 (HealthDay News) -- Most trauma ... make it to their final destination within the two hours ... patients did make it within the time window, ... study in the December issue of the Archives of ...
... By Steven Reinberg HealthDay Reporter , MONDAY, Dec. ... Americans, a new study shows, despite reported links to an ... "spray-on" tans. In fact, about one in every five ... use indoor tanning, University of Minnesota researchers report. "Tanning ...
... -- Most head and neck cancer patients can speak ... but several factors may be associated with poor outcomes, ... who were assessed nearly three years after they were ... cancer. The U.S. researchers gave a speaking score ...
Cached Medicine News:Health News:Quitting menthol cigarettes may be harder for some smokers 2Health News:Blacks with liver cancer more likely to die, study finds 2Health News:Robotic surgery for head and neck cancer shows promise 2Health News:Most Trauma Patients Not Transferred Within Mandated Time Frame in Illinois 2Health News:Most Trauma Patients Not Transferred Within Mandated Time Frame in Illinois 3Health News: Tanning Beds Still Popular Despite Skin Cancer Risk 2Health News: Tanning Beds Still Popular Despite Skin Cancer Risk 3Health News:Speech, Swallowing Usually OK After Head & Neck Cancer Therapy 2
... with the ultimate space efficient engineering ... new Topcon Express Lane the perfect ... practice environments: Ultimate Space EfficiencyComplete, ergonomically ... an 8' X 9' room without ...
... who need to move their imaging system from ... solution. The IMAGEnet Portable System features a rugged ... monitor. This portable PC solution can be coupled ... be tailored to your multi-site imaging needs. The ...
... combines the best 32-bit software package (IMAGEnet ... offerings to bring you a fast reliable ... efficient "mid-resolution" package takes advantage of the ... the latest graphics capture technology and a ...
Inquire...
Medicine Products: